Experimental HCV Drugs
Experimental HCV Drugs
Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 04 March 2013 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2013 conference section
3/4/13
CROI 2013: Progress in Hepatitis C Drug Development [VIDEO]
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Gregory Fowler
Hepatitis C and its treatment has been a key focus at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013), taking place this week in Atlanta. Investigators gave an overview of their research and projections about forthcoming approvals of direct-acting antiviral agents at a morning press conference on Monday.
CROI 2013: Retrovirus Conference Starts Sunday in Atlanta
- Details
- Category: HIV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.
Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.
CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of the direct-acting hepatitis C drugs sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885), and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1, according to data presented today at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
NS5A Inhibitor Daclatasvir Has Dual Mode of Action Against Hepatitis C Virus
- Details
- Category: HCV Treatment
- Published on Wednesday, 20 February 2013 00:00
- Written by Loyola
The promising investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir targets 2 steps of the viral replication process, enabling very rapid HCV RNA reduction, according to a mathematical model described in the February 19, 2013, advance edition of Proceedings of the National Academy of Sciences.
Web Design and Development by